Browsing by Subject "DMARDs (biologic)"

Now showing items 1-2 of 2

    • Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease ... 
      Kavanaugh, Arthur; Lee, Susan J.; Curtis, Jeffrey R.; Greenberg, Jeffrey D.; Kremer, Joel M.; Soto Sáez, Lilian; Etzel, Carol J.; Cox, Vanessa; Yoshida, Kazuki; Reed, George W.; Solomon, Daniel H. (BMJ Publishing Group, 2015)
      Background There is increasing interest in discontinuing biological therapies for patients with rheumatoid arthritis (RA) achieving good clinical responses, provided patients maintain clinical benefit. Methods We ...
    • Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison ... 
      Yoo, Dae Hyun; Prodanovic, Nenad; Jaworski, Janusz; Miranda, Pedro; Ramiterre, Edgar; Lanzon, Allan; Baranauskaite, Asta; Wiland, Piotr; Abud-Mendoza, Carlos; Oparanov, Boycho; Smiyan, Svitlana; Kim, Houng; Lee, Sang Joon; Kim, Suyeon; Park, Won (BMJ Publishing Group, 2017)
      © 2017 Published by the BMJ Publishing Group Limited.Objectives To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing ...